Effects of PCSK9 inhibitors on blood lipids and inflammatory factors in patients with coronary heart disease
10.12092/j.issn.1009-2501.2022.04.009
- Author:
Ruijie WANG
1
;
Liang WANG
1
;
Dan XU
1
;
Miaomiao ZHOU
1
;
Jiming LI
1
Author Information
1. Department of Cardiology, Shanghai East Hospital
- Publication Type:Journal Article
- Keywords:
Blood lipids;
Coronary heart disease;
Inflammatory factors;
PCSK9 inhibitor
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2022;27(4):409-417
- CountryChina
- Language:Chinese
-
Abstract:
AIM: To observe the effect of PCSK9 inhibitors on blood lipid levels and common inflammatory factors in patients with coronary heart disease. METHODS: The clinical data of 201 patients with coronary heart disease who were admitted to the Department of Cardiology of Shanghai East Hospital from April 2020 to June 2021 were retrospectively analyzed. The patients were divided into PCSK9 inhibitor treatment group (101 cases: statin + PCSK9 inhibitor) and control group (100 cases: statin treatment only) according to their medication status. Blood lipids, blood routine, CRP and FIB were re-examined after 1 month of treatment. The changes of blood lipids and inflammatory factors before and after treatment were compared. RESULTS: Before treatment, there was no significant difference in blood lipids, blood routine, CRP and FIB between the two groups (P> 0.05). The levels of sdLDL and Lp(a) were significantly decreased (P< 0.05); the levels of WBC, CRP, N and FIB were significantly decreased (P< 0.05). Compared with the control group, the levels of TC, HDL, LDL-C, CRP and FIB in the PCSK9 inhibitor group were significantly changed (P< 0.05), and the results were statistically significant. CONCLUSION: PCSK9 inhibitors can not only reduce LDL-C levels, but also reduce Lp(a) levels. PCSK9 inhibitors can reduce CRP and FIB levels, suggesting that it can partially improve inflammation in peripheral blood in patients with coronary heart disease.
